KROS
Price
$19.27
Change
-$0.26 (-1.33%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
595M
48 days until earnings call
Intraday BUY SELL Signals
MEOBF
Price
$1.59
Change
-$0.31 (-16.32%)
Updated
Jan 14 closing price
Capitalization
2.3B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KROS vs MEOBF

Header iconKROS vs MEOBF Comparison
Open Charts KROS vs MEOBFBanner chart's image
Keros Therapeutics
Price$19.27
Change-$0.26 (-1.33%)
Volume$5.05K
Capitalization595M
Mesoblast
Price$1.59
Change-$0.31 (-16.32%)
Volume$220
Capitalization2.3B
KROS vs MEOBF Comparison Chart in %
View a ticker or compare two or three
VS
KROS vs. MEOBF commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MEOBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (KROS: $19.53 vs. MEOBF: $1.59)
Brand notoriety: KROS and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 38% vs. MEOBF: 20%
Market capitalization -- KROS: $595M vs. MEOBF: $2.3B
KROS [@Biotechnology] is valued at $595M. MEOBF’s [@Biotechnology] market capitalization is $2.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, both KROS and MEOBF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while MEOBF’s TA Score has 4 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 4 bearish.
  • MEOBF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both KROS and MEOBF are a good buy in the short-term.

Price Growth

KROS (@Biotechnology) experienced а +5.23% price change this week, while MEOBF (@Biotechnology) price change was -16.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

MEOBF is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.3B) has a higher market cap than KROS($595M). KROS YTD gains are higher at: -4.077 vs. MEOBF (-16.316). KROS has higher annual earnings (EBITDA): 68.8M vs. MEOBF (-73.66M). KROS has more cash in the bank: 693M vs. MEOBF (161M). KROS has less debt than MEOBF: KROS (17.4M) vs MEOBF (128M). KROS has higher revenues than MEOBF: KROS (247M) vs MEOBF (17.2M).
KROSMEOBFKROS / MEOBF
Capitalization595M2.3B26%
EBITDA68.8M-73.66M-93%
Gain YTD-4.077-16.31625%
P/E Ratio12.52N/A-
Revenue247M17.2M1,436%
Total Cash693M161M430%
Total Debt17.4M128M14%
FUNDAMENTALS RATINGS
MEOBF: Fundamental Ratings
MEOBF
OUTLOOK RATING
1..100
99
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
56
SEASONALITY SCORE
1..100
13

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KROSMEOBF
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
56%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
43%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
77%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 7 days ago
48%
View a ticker or compare two or three
Interact to see
Advertisement
KROS
Daily Signal:
Gain/Loss:
MEOBF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SOIAX7.930.05
+0.63%
Spirit of America Real Estate Inc&Gr Ins
GSBIX27.780.05
+0.18%
Goldman Sachs Income Builder Instl
GEGCX17.37N/A
N/A
abrdn Emerging Markets C
GCPCX22.08-0.08
-0.36%
Gateway Equity Call Premium C
PRCOX67.96-0.42
-0.61%
T. Rowe Price U.S. Equity Research

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.15%
AXON - KROS
43%
Loosely correlated
-1.92%
DNLI - KROS
39%
Loosely correlated
+0.88%
ALT - KROS
39%
Loosely correlated
+4.24%
CLDX - KROS
39%
Loosely correlated
+1.58%
SPHDF - KROS
38%
Loosely correlated
N/A
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
-16.32%
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
-5.87%
COGT - MEOBF
39%
Loosely correlated
+7.11%
MESO - MEOBF
26%
Poorly correlated
-0.68%
KROS - MEOBF
26%
Poorly correlated
+0.15%
More